Anterogen안트로젠

Anterogen remains loss-making with shrinking value in its shares, though revenue has held up.

Anterogen, a Korean stem cell therapy developer, reported trailing revenue of ₩8.4B and an operating loss of ₩2.5B for the period to H1 2026, with a share price of ₩13,980 on 27 October 2026, down 40.3% over the past year. The company's profile highlights its Cupistem Crohn's fistula treatment and Korean sales rights for two pulmonary hypertension drugs, but the data does not show how much of current revenue comes from each.

What stands out

• Operating margin on a trailing basis is -29.4% and net margin is -17.1%, so losses remain large relative to sales.
• Revenue rose 8.7% in 2025 to ₩7.5B, but operating losses stayed near ₩2.4B, and the company has not reported a profit in the years shown.
• Cash stood at ₩1.7B against free cash flow of -₩1.4B on a trailing basis; borrowings are shown as not available in the data.
• The fair value model gives a base value of ₩1,556 per share, well below the current price; this is a model output, not a forecast, and the data does not include analyst targets.
• Foreign ownership edged up to 4.2% from 4.0% over 60 days, while recent 20-day flows were net negative for foreign and retail investors and positive for institutions.

What to watch

• Several 'major management matter' filings in August to October 2026 are listed by title only; their contents are not in the data and should be checked directly in the filings.
• The half-year report for June 2026 is already filed; the next quarterly figures and any further losses or cash burn will matter given the negative free cash flow.
• The CEO's comments on cartilage regeneration are early-stage in the data; the company's pipeline timing and any regulatory milestones are not provided.